Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 193 to 199 of 199 entries
Sorted by: Best Match Show Resources per page
Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission.

Cardiovascular research

Kalkhoran SB, Kriston-Vizi J, Hernandez-Resendiz S, Crespo-Avilan GE, Rosdah AA, Lees JG, Costa JRSD, Ling NXY, Holien JK, Samangouei P, Chinda K, Yap EP, Riquelme JA, Ketteler R, Yellon DM, Lim SY, Hausenloy DJ.
PMID: 33386841
Cardiovasc Res. 2022 Jan 07;118(1):282-294. doi: 10.1093/cvr/cvaa343.

AIMS: Genetic and pharmacological inhibition of mitochondrial fission induced by acute myocardial ischaemia/reperfusion injury (IRI) has been shown to reduce myocardial infarct size. The clinically used anti-hypertensive and heart failure medication, hydralazine, is known to have anti-oxidant and anti-apoptotic...

Cite
Kalkhoran SB, Kriston-Vizi J, Hernandez-Resendiz S, et al. Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. Cardiovasc Res. 2022;118(1):282-294doi: 10.1093/cvr/cvaa343.
Kalkhoran, S. B., Kriston-Vizi, J., Hernandez-Resendiz, S., Crespo-Avilan, G. E., Rosdah, A. A., Lees, J. G., Costa, J. R. S. D., Ling, N. X. Y., Holien, J. K., Samangouei, P., Chinda, K., Yap, E. P., Riquelme, J. A., Ketteler, R., Yellon, D. M., Lim, S. Y., & Hausenloy, D. J. (2022). Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. Cardiovascular research, 118(1), 282-294. https://doi.org/10.1093/cvr/cvaa343
Kalkhoran, Siavash Beikoghli, et al. "Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission." Cardiovascular research vol. 118,1 (2022): 282-294. doi: https://doi.org/10.1093/cvr/cvaa343
Kalkhoran SB, Kriston-Vizi J, Hernandez-Resendiz S, Crespo-Avilan GE, Rosdah AA, Lees JG, Costa JRSD, Ling NXY, Holien JK, Samangouei P, Chinda K, Yap EP, Riquelme JA, Ketteler R, Yellon DM, Lim SY, Hausenloy DJ. Hydralazine protects the heart against acute ischaemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. Cardiovasc Res. 2022 Jan 07;118(1):282-294. doi: 10.1093/cvr/cvaa343. PMID: 33386841; PMCID: PMC8752357.
Copy Download .nbib Format: NLM
Impact of Intravenous Antihypertensives on Outcomes Among Hospitalized Patients.

American journal of hypertension

Bean-Thompson K, Exposito J, Fowler O, Mhaskar R, Chen L, Codolosa JN.
PMID: 33864360
Am J Hypertens. 2021 Aug 09;34(8):867-873. doi: 10.1093/ajh/hpab060.

BACKGROUND: Many hospitalized patients with acute elevations in blood pressure (BP) are treated with intravenous (IV) antihypertensive medications without evidence of benefit. This study investigated the effects of IV as-needed (PRN) antihypertensives on BP, hospital length of stay, and...

Cite
Bean-Thompson K, Exposito J, Fowler O, et al. Impact of Intravenous Antihypertensives on Outcomes Among Hospitalized Patients. Am J Hypertens. 2021;34(8):867-873doi: 10.1093/ajh/hpab060.
Bean-Thompson, K., Exposito, J., Fowler, O., Mhaskar, R., Chen, L., & Codolosa, J. N. (2021). Impact of Intravenous Antihypertensives on Outcomes Among Hospitalized Patients. American journal of hypertension, 34(8), 867-873. https://doi.org/10.1093/ajh/hpab060
Bean-Thompson, Kelsi, et al. "Impact of Intravenous Antihypertensives on Outcomes Among Hospitalized Patients." American journal of hypertension vol. 34,8 (2021): 867-873. doi: https://doi.org/10.1093/ajh/hpab060
Bean-Thompson K, Exposito J, Fowler O, Mhaskar R, Chen L, Codolosa JN. Impact of Intravenous Antihypertensives on Outcomes Among Hospitalized Patients. Am J Hypertens. 2021 Aug 09;34(8):867-873. doi: 10.1093/ajh/hpab060. PMID: 33864360.
Copy Download .nbib Format: NLM
Pseudomelanosis Duodeni Appearing after Oral Iron Therapy.

Case reports in gastroenterology

Hirai Y, Mori H, Fujimoto A.
PMID: 34594167
Case Rep Gastroenterol. 2021 Jul 29;15(2):689-694. doi: 10.1159/000512400. eCollection 2021.

Pseudomelanosis duodeni is a rare condition characterized by the endoscopic appearance of diffuse dark pigmentation of the duodenal mucosa. It is typically seen in older women and has been reported to be associated with hypertension, chronic renal disease, diabetes...

Cite
Hirai Y, Mori H, Fujimoto A. Pseudomelanosis Duodeni Appearing after Oral Iron Therapy. Case Rep Gastroenterol. 2021;15(2):689-694doi: 10.1159/000512400.
Hirai, Y., Mori, H., & Fujimoto, A. (2021). Pseudomelanosis Duodeni Appearing after Oral Iron Therapy. Case reports in gastroenterology, 15(2), 689-694. https://doi.org/10.1159/000512400
Hirai, Yuichiro, et al. "Pseudomelanosis Duodeni Appearing after Oral Iron Therapy." Case reports in gastroenterology vol. 15,2 (2021): 689-694. doi: https://doi.org/10.1159/000512400
Hirai Y, Mori H, Fujimoto A. Pseudomelanosis Duodeni Appearing after Oral Iron Therapy. Case Rep Gastroenterol. 2021 Jul 29;15(2):689-694. doi: 10.1159/000512400. eCollection 2021. PMID: 34594167; PMCID: PMC8436605.
Copy Download .nbib Format: NLM
Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke.

The American journal of emergency medicine

Kamp A, Huang W, Lassiter T, Shah S, Liu B, Kram B.
PMID: 34959025
Am J Emerg Med. 2021 Nov 29;52:220-224. doi: 10.1016/j.ajem.2021.11.037. Epub 2021 Nov 29.

BACKGROUND: The optimal approach to blood pressure (BP) management in acute ischemic stroke remains unclear. The purpose of this study was to determine if an intermittent (labetalol or hydralazine) or continuous infusion (nicardipine or clevidipine) antihypertensive strategy facilitated timelier...

Cite
Kamp A, Huang W, Lassiter T, et al. Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke. Am J Emerg Med. 2021;52:220-224doi: 10.1016/j.ajem.2021.11.037.
Kamp, A., Huang, W., Lassiter, T., Shah, S., Liu, B., & Kram, B. (2021). Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke. The American journal of emergency medicine, 52220-224. https://doi.org/10.1016/j.ajem.2021.11.037
Kamp, Ashley, et al. "Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke." The American journal of emergency medicine vol. 52 (2021): 220-224. doi: https://doi.org/10.1016/j.ajem.2021.11.037
Kamp A, Huang W, Lassiter T, Shah S, Liu B, Kram B. Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke. Am J Emerg Med. 2021 Nov 29;52:220-224. doi: 10.1016/j.ajem.2021.11.037. Epub 2021 Nov 29. PMID: 34959025.
Copy Download .nbib Format: NLM
The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators.

Fundamental & clinical pharmacology

Suarez-Torres JD, Orozco CA, Ciangherotti CE.
PMID: 33772863
Fundam Clin Pharmacol. 2021 Dec;35(6):1069-1089. doi: 10.1111/fcp.12674. Epub 2021 Apr 27.

The nonclinical branch of regulatory pharmacology has traditionally relied on the sensitivity and specificity of regulatorily recommended bioassays. Nonetheless, any predictive testing (eg, safety pharmacology) with less than 100% sensitivity or 100% specificity is prone to deliver false positive...

Cite
Suarez-Torres JD, Orozco CA, Ciangherotti CE. The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators. Fundam Clin Pharmacol. 2021;35(6):1069-1089doi: 10.1111/fcp.12674.
Suarez-Torres, J. D., Orozco, C. A., & Ciangherotti, C. E. (2021). The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators. Fundamental & clinical pharmacology, 35(6), 1069-1089. https://doi.org/10.1111/fcp.12674
Suarez-Torres, Jose D, et al. "The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators." Fundamental & clinical pharmacology vol. 35,6 (2021): 1069-1089. doi: https://doi.org/10.1111/fcp.12674
Suarez-Torres JD, Orozco CA, Ciangherotti CE. The numerical probability of carcinogenicity to humans of some pharmaceutical drugs: Alkylating agents, topoisomerase inhibitors or poisons, and DNA intercalators. Fundam Clin Pharmacol. 2021 Dec;35(6):1069-1089. doi: 10.1111/fcp.12674. Epub 2021 Apr 27. PMID: 33772863.
Copy Download .nbib Format: NLM
Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana.

BMC nephrology

Okyere P, Ephraim RKD, Okyere I, Attakorah J, Serwaa D, Essuman G, Abaka-Yawson A, Adoba P.
PMID: 33910506
BMC Nephrol. 2021 Apr 28;22(1):156. doi: 10.1186/s12882-021-02336-8.

BACKGROUND: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the commonest of the hereditary kidney diseases and mostly ensues in utero with signs delayed until after several decades. This study assessed the demographic, diagnostic (clinical and biochemical features) and therapeutic...

Cite
Okyere P, Ephraim RKD, Okyere I, et al. Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana. BMC Nephrol. 2021;22(1):156doi: 10.1186/s12882-021-02336-8.
Okyere, P., Ephraim, R. K. D., Okyere, I., Attakorah, J., Serwaa, D., Essuman, G., Abaka-Yawson, A., & Adoba, P. (2021). Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana. BMC nephrology, 22(1), 156. https://doi.org/10.1186/s12882-021-02336-8
Okyere, Perditer, et al. "Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana." BMC nephrology vol. 22,1 (2021): 156. doi: https://doi.org/10.1186/s12882-021-02336-8
Okyere P, Ephraim RKD, Okyere I, Attakorah J, Serwaa D, Essuman G, Abaka-Yawson A, Adoba P. Demographic, diagnostic and therapeutic characteristics of autosomal dominant polycystic kidney disease in Ghana. BMC Nephrol. 2021 Apr 28;22(1):156. doi: 10.1186/s12882-021-02336-8. PMID: 33910506; PMCID: PMC8080413.
Copy Download .nbib Format: NLM
Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes.

Drug metabolism and pharmacokinetics

Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H.
PMID: 34624627
Drug Metab Pharmacokinet. 2021 Dec;41:100419. doi: 10.1016/j.dmpk.2021.100419. Epub 2021 Aug 24.

The epidermal growth factor receptor inhibitor BIBX1382 has failed in drug development because of poor oral exposure and low bioavailability associated with its extensive metabolism by aldehyde oxidase (AOX) in humans. In this study, we investigated the metabolic profiles...

Cite
Uehara S, Yoneda N, Higuchi Y, et al. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. Drug Metab Pharmacokinet. 2021;41:100419doi: 10.1016/j.dmpk.2021.100419.
Uehara, S., Yoneda, N., Higuchi, Y., Yamazaki, H., & Suemizu, H. (2021). Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. Drug metabolism and pharmacokinetics, 41100419. https://doi.org/10.1016/j.dmpk.2021.100419
Uehara, Shotaro, et al. "Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes." Drug metabolism and pharmacokinetics vol. 41 (2021): 100419. doi: https://doi.org/10.1016/j.dmpk.2021.100419
Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H. Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. Drug Metab Pharmacokinet. 2021 Dec;41:100419. doi: 10.1016/j.dmpk.2021.100419. Epub 2021 Aug 24. PMID: 34624627.
Copy Download .nbib Format: NLM
Showing 193 to 199 of 199 entries